Author

D. K. Inaoka

Primary ORCID profile (0000-0002-9791-927X · 2 papers)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

D. K. InaokaiD2 papers · Nagasaki University

Biology Disciplines

Click to filter author papers

Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:non-human primate· 1

Frequent Co-Authors

J. Yasuda· 1 shared K. Fujine· 1 shared K. Kita· 1 shared K. Morita· 1 shared M. M. N. Tun· 1 shared T. Sakura· 1 shared Y. Kurosaki· 1 shared Y. Sakurai· 1 shared

Activity by Year

2020-2020 · peak 1/yr

Co-Author Collaboration Network

8 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

J. Yasuda

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

5-amino levulinic acid inhibits SARS-CoV-2 infection in vitro

Y. Sakurai, M. M. N. Tun, Y. Kurosaki, T. Sakura, D. K. Inaoka, K. Fujine, K. Kita, K. Morita, J. Yasuda

This study shows that 5-ALA inhibits SARS-CoV-2 infection in vitro in both human and non-human cells with low cytotoxicity, suggesting it as a potential oral antiviral drug for COVID-19.

bioRxiv · Oct 28, 2020Microbiology